2010

Print

Date Release Download
December 15 Lundbeck Embarks on Research Initiative to Identify and Develop Therapies that May Slow or Halt the Progression of Huntington’s Disease
December 04 Lundbeck Reports Positive Phase III Study Results for Clobazam
November 17 Lundbeck Names Staffan Schüberg as President of Lundbeck Inc. U.S. Subsidiary
September 09 Lundbeck wins Federal Trade Commission case in Federal District Court
July 30 Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) Injection
May 19 Lundbeck Inc. Receives 2010 Corporate Award from National Organization for Rare Disorders
May 05 Join Lundbeck and the Hereditary Disease Foundation to Build Hope for HD During Huntington’s Disease (HD) Awareness Month
March 05 Open-label Continuation Study Supports Long-term Efficacy of Xenazine® (tetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease
February 08 Raise Your Hand in Support of Millions of Americans
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck Inc. does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck Inc. is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck Inc.